A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

Phase 3 Terminated 1061 enrolled Areteia Therapeutics

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.

Timeline

Start: 2023-01-30
Primary completion: 2025-12-08
Completion: 2025-12-08

Outcome

Outcome not reported

Stopped: “Program stopped due to the benefit risk profile no longer supports further development in the intended patient population.”

Publications

Seluk L, Davis AE, Rhoads S, Wechsler ME. Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma. Ann Allergy Asthma Immunol. 2025 Jan;134(1):9-18. doi: 10.1016/j.anai.2024.09.016. Epub 2024 Oct 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexpramipexole	Small molecule	75 mg	Oral
Subject	Dexpramipexole	Small molecule	150 mg	Oral